(Q34651051)

3 August 2017

title

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation (English)

1 reference

European Heart Rhythm Association

3 August 2017

0 references

0 references

1 reference

1 reference

Paulus Kirchhof

9

0 references

10

object named as

European Heart Rhythm Association

1 reference

3 August 2017

6

Jonas Oldgren

1 reference

3 August 2017

1

Hein Heidbuchel

1 reference

3 August 2017

8

A John Camm

1 reference

3 August 2017

Peter Verhamme

2

1 reference

3 August 2017

Marco Alings

3

1 reference

3 August 2017

Matthias Antz

4

1 reference

3 August 2017

Werner Hacke

5

1 reference

3 August 2017

Peter Sinnaeve

7

1 reference

3 August 2017

publication date

1 May 2013

1 reference

3 August 2017

1 reference

3 August 2017

volume

15

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

625-651

1 reference

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Apixaban in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Assays for measuring rivaroxaban: their suitability and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Apixaban metabolism and pharmacokinetics after oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Rivaroxaban in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Apixaban with antiplatelet therapy after acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Safe use of hemodialysis for dabigatran removal before cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Oral anticoagulation in surgical procedures: risks and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

The use of dabigatran immediately after atrial fibrillation ablation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Warfarin, aspirin, or both after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUT083

21 January 2018

Identifiers

DOI

10.1093/EUROPACE/EUT083

1 reference

3 August 2017

1 reference